Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-03-11
2008-03-11
Shameem, Golam M. M. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S469000, C548S490000, C548S491000, C548S146000, C548S182000, C548S215000, C548S229000, C548S125000, C548S129000, C548S132000, C548S250000, C548S252000, C548S240000, C548S243000, C548S262200, C548S364700, C514S361000, C514S364000, C514S372000, C514S381000
Reexamination Certificate
active
07342039
ABSTRACT:
The present invention relates to substituted indole oximes and methods of using them.
REFERENCES:
patent: 3026325 (1962-03-01), Heinzelman et al.
patent: 3476770 (1969-11-01), Sherrer
patent: 3557142 (1971-01-01), Bell
patent: 3843683 (1974-10-01), Bell
patent: 4478819 (1984-10-01), Hercelin et al.
patent: 4736043 (1988-04-01), Mechel et al.
patent: 4851406 (1989-07-01), Martens et al.
patent: 5104872 (1992-04-01), Tsubata et al.
patent: 5164372 (1992-11-01), Matsuo et al.
patent: 5420289 (1995-05-01), Musser et al.
patent: 5436267 (1995-07-01), Komyoji et al.
patent: 5482960 (1996-01-01), Berryman
patent: 5502187 (1996-03-01), Ayer et al.
patent: 5541343 (1996-07-01), Himmelsbach et al.
patent: 5599663 (1997-02-01), Vaughan
patent: 5612360 (1997-03-01), Boyd et al.
patent: 5859044 (1999-01-01), Dow et al.
patent: 6048875 (2000-04-01), De Nanteuil et al.
patent: 6110963 (2000-08-01), Malamas
patent: 6166069 (2000-12-01), Malamas et al.
patent: 6232322 (2001-05-01), Malamas et al.
patent: 6302837 (2001-10-01), De Nanteuil et al.
patent: 6479524 (2002-11-01), Priepke et al.
patent: 6599929 (2003-07-01), Cho et al.
patent: 6787556 (2004-09-01), Hargreaves et al.
patent: 6800645 (2004-10-01), Cox et al.
patent: 6800654 (2004-10-01), Mayer et al.
patent: 6844358 (2005-01-01), Malamas et al.
patent: 2003/0013732 (2003-01-01), Elokdah
patent: 2003/0018067 (2003-01-01), Elokdah et al.
patent: 2003/0060497 (2003-03-01), Gerlach et al.
patent: 2003/0125371 (2003-07-01), Elokdah et al.
patent: 2004/0116488 (2004-06-01), Jennings et al.
patent: 2004/0116504 (2004-06-01), Elokdah et al.
patent: 2004/0122070 (2004-06-01), Jennings
patent: 2004/0138283 (2004-07-01), Jennings et al.
patent: 2004/0204417 (2004-10-01), Perez et al.
patent: 2005/0070584 (2005-03-01), Havran et al.
patent: 2005/0070585 (2005-03-01), Elokdah et al.
patent: 2005/0070587 (2005-03-01), Elokdah et al.
patent: 2005/0070592 (2005-03-01), Gundersen
patent: 2005/0096377 (2005-05-01), Hu
patent: 2005/0113428 (2005-05-01), Gopalsamy et al.
patent: 2005/0113436 (2005-05-01), Elokdah et al.
patent: 2005/0113438 (2005-05-01), Hu et al.
patent: 2005/0113439 (2005-05-01), Hu
patent: 2005/0119296 (2005-06-01), Elokdah et al.
patent: 2005/0119327 (2005-06-01), Hu
patent: 2005/0215626 (2005-09-01), Havran et al.
patent: 3147276 (1981-11-01), None
patent: 43 38 770 (1995-05-01), None
patent: 19543639 (1997-05-01), None
patent: 19753522 (1999-06-01), None
patent: 0 414 153 (1991-02-01), None
patent: 0 416 609 (1991-03-01), None
patent: 0 498 396 (1992-08-01), None
patent: 0 508 723 (1992-10-01), None
patent: 0 512 570 (1992-11-01), None
patent: 0 540 956 (1993-05-01), None
patent: 0 564 984 (1993-10-01), None
patent: 0 655 439 (1995-05-01), None
patent: 0 759 434 (1997-02-01), None
patent: 0 819 686 (1998-01-01), None
patent: 0 822 185 (1998-02-01), None
patent: 708 098 (1999-03-01), None
patent: 0 916 651 (1999-05-01), None
patent: 0 955 299 (1999-11-01), None
patent: 1 092 716 (2001-04-01), None
patent: 1 156 045 (2001-11-01), None
patent: 2 244 499 (1975-04-01), None
patent: 2 777 886 (1999-10-01), None
patent: 2 799 756 (2001-04-01), None
patent: 1 321 433 (1973-06-01), None
patent: WO92/18487 (1992-10-01), None
patent: WO94/13637 (1994-06-01), None
patent: 94/14434 (1994-07-01), None
patent: 94/26738 (1994-11-01), None
patent: 95/10513 (1995-04-01), None
patent: WO95/29907 (1995-11-01), None
patent: 96/06840 (1996-03-01), None
patent: 96/21656 (1996-07-01), None
patent: 96/26207 (1996-08-01), None
patent: WO96/32379 (1996-10-01), None
patent: 97/09308 (1997-03-01), None
patent: WO97/37970 (1997-10-01), None
patent: 97/43260 (1997-11-01), None
patent: 97/48697 (1997-12-01), None
patent: 98/08818 (1998-03-01), None
patent: WO98/23155 (1998-06-01), None
patent: 99/28297 (1999-06-01), None
patent: 99/43651 (1999-09-01), None
patent: 99/43654 (1999-09-01), None
patent: 99/43672 (1999-09-01), None
patent: 99/46260 (1999-09-01), None
patent: WO99/43651 (1999-09-01), None
patent: WO99/43654 (1999-09-01), None
patent: WO99/46263 (1999-09-01), None
patent: 99/50268 (1999-10-01), None
patent: 99/58519 (1999-11-01), None
patent: 99/61435 (1999-12-01), None
patent: 00/32180 (2000-06-01), None
patent: 00/35919 (2000-06-01), None
patent: WO 00/37436 (2000-06-01), None
patent: 00/46195 (2000-08-01), None
patent: 00/46197 (2000-08-01), None
patent: 00/64876 (2000-11-01), None
patent: 00/64888 (2000-11-01), None
patent: 01/12187 (2001-02-01), None
patent: 02/030895 (2002-04-01), None
patent: 02/072549 (2002-09-01), None
patent: 03/000253 (2003-01-01), None
patent: 03/031409 (2003-04-01), None
patent: 03/068742 (2003-08-01), None
patent: 03/087087 (2003-10-01), None
patent: 2004/052854 (2004-06-01), None
U.S. Appl. No. 10/947,710, filed Sep. 23, 2004, Commons et al.
U.S. Appl. No. 10/947,711, filed Sep. 23, 2004, Gopalsamy et al.
U.S. Appl. No. 11/208,777, filed Aug. 22, 2005, Commons et al.
U.S. Appl. No. 11/208,772, filed Aug. 22, 2005, Commons.
U.S. Appl. No. 11/208,775, filed Aug. 22, 2005, Commons et al.
Charlton, Peter, “The status of plasminogen activator inhibitor-1 as a therapeutic target,”Expert Opinion On Investigational Drugs, May 1997, 6(5), 539-554.
Crandall, D. L. et al., “Characterization and comparative evaluation of a structurally unique PAI-1 inhibitor exhibiting oral in-vivo efficacy,”Journal of Thrombosis and Haemostasis, Mar. 17, 2004, 1422-1428.
Da Settimo, A. et al., “Reaction of indole derivatives with bromine, substitution, oxidation, and dimerization,” J Org Chem, 1970, 35(8), 2546-2551.
Guzzo, P.R. et al., “Synthesis of a conformationally constrained threonin-valine dipeptide mimetic: design of a potential inhibitor of plasminogen activator inhibitor-1,”Tetrahedron Letters, 2002 43(1), 41-43.
Malamas, M.S. et al. “Novel benzofuran and benzothiophene biphenyls as inhibitors of protein tyrosine phosphatase 1B with antihyperglycemic properties,”Journal of Medicinal Chemistry, Apr. 6, 2000, 43(7), 1293-1310.
Aggarwal et al., “A catalytic antibody programmed for torsional activation of amide bond hydrolysis,”Chem. Eur. J., Jan. 25, 2003, 9(13), 3132-3142.
Ballantine, J. A., “The Chemistry of Bacteria,”Journal of the Chemical Society Abstracts, 1957, 2222-2227.
Delgado et al., Journal of Organic Chemistry (1993), 58(10), pp. 2862-2866.
Dillard R. D. et al., “Indole Inhibitors of Human Nonpancreatic Secretory Phospholipase A21. Indole-3-Acetamides”,Journal of Medicinal Chemistry, American Chemical Society, 39(26), 5119-5136.
Hipskind, P. A. et al., “Potent and selective 1,2,3-trisubstituted indole NPY Y-1 antagonists,”J Med Chem, 1997, 40(23), 3712-3714.
Julia et al., CA 57:49169, 1962.
Malamas, M. S. et al., “Antihyperglycemic activity of new 1,2,4-oxadiazolidine-3,5-diones,”Eur. J. Med. Chem., 2001, 36, 31-42.
Moody et al., CA 120:298300, 1994.
Shengeliya, M. S. et al., “N-Glycosides of 5-amino-2-(ethoxycarbonyl)indole,”Zhurnal Organicheskoi Khimii, 1986, 22(9),1868-1873.
Krishnamurti, C. et al., “Plasminogen Activator Inhibitor: A Regulator of Ancrod-Induced Fibrin Deposition in Rabbits,”Blood, 69(3): 798-803 (Mar. 1987).
Reilly, C. et al., “Both Circulating and Clot-Bound Plasminogen Activator-1 Inhibit Endogenous Fibrinolysis in the Rat,”Arteriosclerosis and Thrombosis, 11(5): 1276-1286 (Sep./Oct. 1991).
Carmeliet, P. et al., “Plasminogen Activator Inhibitor-1 Gene-deficient Mice,”Journal of Clinical Investigation, 92:2756-2760 (Dec. 1993).
Rocha, E. et al., “The Relationship Between Impaired Fibrinolysis and Coronary Heart Disease,”Fibrinolysis, 8: 294-303 (1994).
Aznar, J. et al., “Role of Plasminogen Activator Inhibitor Type 1 in the Pathogenesis of Coronary Artery Diseases,”Haemostasis24: 243-251 (1994).
Biemond, B. J. et al., “Thrombolysis and Reocclusion in Experimental Jugular Vein and Coronary Artery Thrombosis,”Circulation, 91: 1175-1181 (1995).
Levi, M. et al., “Inhibiti
Butera John Anthony
Elokdah Hassan Mahmoud
Gundersen Eric Gould
Havran Lisa Marie
Jenkins Douglas John
Ng Mabel
Shameem Golam M. M.
Wyeth
LandOfFree
Substituted indole oximes does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted indole oximes, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted indole oximes will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2787586